Aurobindo Pharma has surged nearly 9% at Rs 259, also its 52-week high on BSE, after reporting a healthy 80% year-on-year (yoy) growth in consolidated adjusted net profit at Rs 245 crore for the quarter ended September 30, 2013 (Q2) on back of strong operational performance. The pharmaceutical company had profit of Rs 136 crore in a year ago quarter.
Net sales grew strongly by 28.1% yoy to Rs 1,897 crore led by a robust growth in formulations. The growth in formulation was driven by the USA markets, which posted a yoy growth of 72.0%.
The EBITDA margin during the quarter has improved by 620bps yoy at 22.9% due to improved business mix resulting in decrease in materials consumption, staff cost and other expenses to net operating income, Aurobindo Pharma said in a statement.
The counter has seen huge trading activities with a combined 8.02 million shares already changed hands till 1010 hours against an average sub 2 million shares that were traded daily in past two weeks on BSE and NSE.
Net sales grew strongly by 28.1% yoy to Rs 1,897 crore led by a robust growth in formulations. The growth in formulation was driven by the USA markets, which posted a yoy growth of 72.0%.
The EBITDA margin during the quarter has improved by 620bps yoy at 22.9% due to improved business mix resulting in decrease in materials consumption, staff cost and other expenses to net operating income, Aurobindo Pharma said in a statement.
The counter has seen huge trading activities with a combined 8.02 million shares already changed hands till 1010 hours against an average sub 2 million shares that were traded daily in past two weeks on BSE and NSE.
